CAREERS
OUR PEOPLE
Licensing agreement between Laekna and Novartis
On July 09th 2017 , Laekna acquired the global rights from Novartis Pharma AG to develop, manufacture and commercialize small molecule candidate LAE001 (previously known as CFG920) for prostate cancer. LAE001 has been previously studied in phase II clinical trial in the United States, and demonstrated satisfactory efficacy and safety profile in metastatic castration prostate cancer patients. Laekna are committed to deliver this drug further to regulatory approval in China and the rest of the world.
Popular recommendations
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
Follow us on Linkedin
Copyright © Laekna Therapeutics, All Rights Reserved. Privacy Policy
